Arbutus Biopharma (ABUS) Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings or view top-rated stocks.

3 Wall Street research analysts have issued 12 month price targets for Arbutus Biopharma's stock. Their ABUS share price forecasts range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 141.9% from the stock's current price.
View analysts price targets for ABUS or view top-rated stocks among Wall Street analysts.

Arbutus Biopharma's stock was trading at $2.33 at the beginning of 2023. Since then, ABUS stock has increased by 6.4% and is now trading at $2.48.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our ABUS earnings forecast.

Arbutus Biopharma Co. (NASDAQ:ABUS) released its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, meeting the consensus estimate of ($0.24). The biopharmaceutical company earned $3.34 million during the quarter, compared to the consensus estimate of $2.36 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 48.34% and a negative net margin of 211.41%. During the same period in the previous year, the firm earned ($0.27) earnings per share.

ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), iShares Genomics Immunology and Healthcare ETF (IDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Invesco Nasdaq Future Gen 200 ETF (QQQS), ALPS Medical Breakthroughs ETF (SBIO), Principal Healthcare Innovators ETF (BTEC) and Invesco Nasdaq Biotechnology ETF (IBBQ).

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

Arbutus Biopharma trades on the NASDAQ under the ticker symbol "ABUS."

Arbutus Biopharma's stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (5.09%), Whitefort Capital Management LP (4.51%), Rubric Capital Management LP (2.53%), Hudson Bay Capital Management LP (1.65%), Geode Capital Management LLC (1.38%) and State Street Corp (1.24%).
View institutional ownership trends.

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ABUS stock can currently be purchased for approximately $2.48.

Arbutus Biopharma (NASDAQ:ABUS) has a market capitalization of $412.00 million and generates $39.02 million in revenue each year. The biopharmaceutical company earns $-69,460,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis.

Arbutus Biopharma's mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The official website for the company is www.arbutusbio.com. The biopharmaceutical company can be reached via phone at (267) 469-0914, via email at ir@arbutusbio.com, or via fax at 604-419-3201.